» Articles » PMID: 29884741

Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma

Abstract

Understanding the profile of oncogene and tumor suppressor gene mutations with their interactions and impact on the prognosis of multiple myeloma (MM) can improve the definition of disease subsets and identify pathways important in disease pathobiology. Using integrated genomics of 1273 newly diagnosed patients with MM, we identified 63 driver genes, some of which are novel, including , , , , and Oncogene mutations are significantly more clonal than tumor suppressor mutations, indicating they may exert a bigger selective pressure. Patients with more driver gene abnormalities are associated with worse outcomes, as are identified mechanisms of genomic instability. Oncogenic dependencies were identified between mutations in driver genes, common regions of copy number change, and primary translocation and hyperdiploidy events. These dependencies included associations with t(4;14) and mutations in , , and ; t(11;14) with mutations in and ; t(14;16) with mutations in , , , and ; and hyperdiploidy with gain 11q, mutations in , and rearrangements. These associations indicate that the genomic landscape of myeloma is predetermined by the primary events upon which further dependencies are built, giving rise to a nonrandom accumulation of genetic hits. Understanding these dependencies may elucidate potential evolutionary patterns and lead to better treatment regimens.

Citing Articles

Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.

Chen X, Luo T, Zhang W, Wang S, Zhu M, He H BMC Med Genomics. 2025; 18(1):50.

PMID: 40087669 DOI: 10.1186/s12920-025-02116-5.


Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.

Hosoya H, Carleton M, Tanaka K, Sworder B, Syal S, Sahaf B Nat Commun. 2025; 16(1):1824.

PMID: 39979252 PMC: 11842827. DOI: 10.1038/s41467-025-56486-6.


Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.

Mohan Lal B, van Rhee F, Al Hadidi S Curr Oncol Rep. 2025; .

PMID: 39937351 DOI: 10.1007/s11912-025-01639-5.


Survival outcome prediction of esophageal squamous cell carcinoma patients based on radiomics and mutation signature.

Yan T, Yan Z, Chen G, Xu S, Wu C, Zhou Q Cancer Imaging. 2025; 25(1):9.

PMID: 39891186 PMC: 11783911. DOI: 10.1186/s40644-024-00821-5.


Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets.

Moreno Rueda L, Wang H, Akagi K, Dang M, Vora A, Qin L Cell Rep Med. 2025; 6(2):101925.

PMID: 39855192 PMC: 11866523. DOI: 10.1016/j.xcrm.2024.101925.


References
1.
Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A . Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015; 47(12):1408-10. PMC: 4954601. DOI: 10.1038/ng.3427. View

2.
Walker B, Wardell C, Murison A, Boyle E, Begum D, Dahir N . APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015; 6:6997. PMC: 4568299. DOI: 10.1038/ncomms7997. View

3.
Boone D, Qi Y, Li Z, Hann S . Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci U S A. 2010; 108(2):632-7. PMC: 3021028. DOI: 10.1073/pnas.1008848108. View

4.
Garnett M, Marais R . Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004; 6(4):313-9. DOI: 10.1016/j.ccr.2004.09.022. View

5.
Shen M . Chromoplexy: a new category of complex rearrangements in the cancer genome. Cancer Cell. 2013; 23(5):567-9. PMC: 3673705. DOI: 10.1016/j.ccr.2013.04.025. View